GLAND PHARMA
Quarterly Results Analysis [Sep2024]
GLAND PHARMA Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,406 Cr | ₹1,402 Cr | ₹1,537 Cr | ₹1,545 Cr | ₹1,373 Cr | ₹1,209 Cr | ₹785 Cr | ₹938 Cr |
Expenses | ₹1,109 Cr | ₹1,137 Cr | ₹1,179 Cr | ₹1,189 Cr | ₹1,049 Cr | ₹915 Cr | ₹617 Cr | ₹649 Cr |
Operating Income | ₹297 Cr | ₹264 Cr | ₹359 Cr | ₹356 Cr | ₹324 Cr | ₹294 Cr | ₹168 Cr | ₹290 Cr |
Other Income | ₹60 Cr | ₹51 Cr | ₹42 Cr | ₹37 Cr | ₹53 Cr | ₹38 Cr | ₹39 Cr | ₹62 Cr |
Interest | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr |
Depreciation | ₹94 Cr | ₹92 Cr | ₹93 Cr | ₹105 Cr | ₹81 Cr | ₹65 Cr | ₹38 Cr | ₹38 Cr |
Profit Before Tax | ₹257 Cr | ₹218 Cr | ₹298 Cr | ₹283 Cr | ₹290 Cr | ₹261 Cr | ₹111 Cr | ₹311 Cr |
Profit After Tax | ₹164 Cr | ₹144 Cr | ₹192 Cr | ₹192 Cr | ₹194 Cr | ₹194 Cr | ₹79 Cr | ₹232 Cr |
EPS | ₹9.93 | ₹8.73 | ₹11.68 | ₹11.65 | ₹11.78 | ₹11.79 | ₹4.78 | ₹14.08 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAND PHARMA | 0.9% | 0.2% | -2.5% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 0.7% | 47.3% |
CIPLA | 0.3% | -1.8% | 19.6% |
DR REDDYS LABORATORIES | 6% | 11.8% | 20.3% |
ZYDUS LIFESCIENCES | -1.5% | -0.1% | 47% |
DIVIS LABORATORIES | -1.1% | -5.8% | 61.7% |
MANKIND PHARMA | 3.7% | 11.4% | 59.4% |
TORRENT PHARMACEUTICALS | 0.6% | 4.1% | 59.5% |
LUPIN | 3.3% | 2.9% | 75.9% |
GLAND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 0.29 % |
Y-o-Y | 2.36 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹1,406 Cr | 0.29 | |
Jun2024 | ₹1,402 Cr | -8.83 | |
Mar2024 | ₹1,537 Cr | -0.50 | |
Dec2023 | ₹1,545 Cr | 12.50 | |
Sep2023 | ₹1,373 Cr | 13.63 | |
Jun2023 | ₹1,209 Cr | 53.97 | |
Mar2023 | ₹785 Cr | -16.34 | |
Dec2022 | ₹938 Cr | - |
GLAND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 12.35 % |
Y-o-Y | -8.34 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹297 Cr | 12.35 | |
Jun2024 | ₹264 Cr | -26.28 | |
Mar2024 | ₹359 Cr | 0.63 | |
Dec2023 | ₹356 Cr | 9.97 | |
Sep2023 | ₹324 Cr | 10.25 | |
Jun2023 | ₹294 Cr | 74.54 | |
Mar2023 | ₹168 Cr | -41.84 | |
Dec2022 | ₹290 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 12.04 % |
Y-o-Y | -10.47 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 21.13% | 12.04 | |
Jun2024 | 18.86% | -19.16 | |
Mar2024 | 23.33% | 1.17 | |
Dec2023 | 23.06% | -2.29 | |
Sep2023 | 23.6% | -2.96 | |
Jun2023 | 24.32% | 13.38 | |
Mar2023 | 21.45% | -30.49 | |
Dec2022 | 30.86% | - |
GLAND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 13.75 % |
Y-o-Y | -15.74 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹164 Cr | 13.75 | |
Jun2024 | ₹144 Cr | -25.29 | |
Mar2024 | ₹192 Cr | 0.29 | |
Dec2023 | ₹192 Cr | -1.15 | |
Sep2023 | ₹194 Cr | -0.01 | |
Jun2023 | ₹194 Cr | 146.69 | |
Mar2023 | ₹79 Cr | -66.08 | |
Dec2022 | ₹232 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 13.35 % |
Y-o-Y | -17.69 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 11.63 % | 13.35 | |
Jun2024 | 10.26 % | -18.05 | |
Mar2024 | 12.52 % | 0.81 | |
Dec2023 | 12.42 % | -12.10 | |
Sep2023 | 14.13 % | -12.02 | |
Jun2023 | 16.06 % | 60.28 | |
Mar2023 | 10.02 % | -59.47 | |
Dec2022 | 24.72 % | - |
GLAND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 13.75 % |
Y-o-Y | -15.70 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹9.93 | 13.75 | |
Jun2024 | ₹8.73 | -25.26 | |
Mar2024 | ₹11.68 | 0.26 | |
Dec2023 | ₹11.65 | -1.10 | |
Sep2023 | ₹11.78 | -0.08 | |
Jun2023 | ₹11.79 | 146.65 | |
Mar2023 | ₹4.78 | -66.05 | |
Dec2022 | ₹14.08 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD